^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
INCA32459
i
Other names: INCA32459, INCA32459-101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Incyte, Merus
Drug class:
PD1 inhibitor, LAG-3 inhibitor
Related drugs:
over1year
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies (clinicaltrials.gov)
P1, N=120, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
INCA32459
over1year
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies (clinicaltrials.gov)
P1, N=120, Not yet recruiting, Incyte Corporation
New P1 trial • Metastases
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
INCA32459
over1year
A human bispecific antibody targeting LAG-3 and PD-1 (INCA32459) potently activates exhausted T cells (SITC 2022)
In a human MDA-MB-231 breast tumor model in CD34 + humanized NSG mice, INCA32459 treatment decreased tumor growth compared with a combination of PD-1 (pembrolizumab) and LAG-3 (relatlimab analog) antibodies. Conclusions We have developed INCA32459, a potent dual inhibitor of PD-1 and LAG-3 in preclinical models, which induces activation of exhausted T cells to a greater extent than a combination of bivalent monospecific antibodies targeting PD-1 (nivolumab analog) and LAG-3 (relatlimab analog). These data support the clinical evaluation of INCA32459, and a phase 1 study in cancer patients is underway.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3) • CD34 (CD34 molecule) • IL2 (Interleukin 2)
|
LAG3 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • relatlimab (BMS-986016) • INCA32459
Share via
